{{Rsnum
|rsid=1604079
|Gene=KSR2
|Chromosome=12
|position=117500714
|Orientation=minus
|GMAF=0.3287
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=KSR2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 17.7 | 61.3 | 21.0
| HCB | 9.5 | 31.0 | 59.5
| JPT | 7.0 | 55.8 | 37.2
| YRI | 3.3 | 26.2 | 70.5
| ASW | 0.0 | 0.0 | 0.0
| CHB | 9.5 | 31.0 | 59.5
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1604079
|Name_s=
|Gene_s=KSR2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.000003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109341
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1604079
|overall_frequency_n=41
|overall_frequency_d=128
|overall_frequency=0.320312
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=31
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}